You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 59 Next »

Project Scope

This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.

Project LeadsEmails

Mary Nilsson, Eli Lilly

nilsson_mary_e@lilly.com

William Palo, Abbvie

william.palo@abbvie.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q4 2023

  • Release White Paper for public review by Q4

Objectives & Deliverables 

Timelines 

Project team review final White Paper 

Q2 2023
PHUSE Steering Committee & Public Review Q3 2023
Publish White PaperQ4 2023
  • No labels